论文部分内容阅读
目的:观察替尼泊甙和顺铂联合脑部放射治疗肺癌脑转移患者的疗效、不良反应和生存率。方法:替尼泊甙100mg,第1天到第3天;顺铂40mg,第1天到第3天,21d为1个周期。脑部放疗于第1个周期化疗开始后第5天开始,DT(1.8~2.0)Gy/次,1次/d,5次/周,单个病灶者全颅放疗DT30Gy后缩野追加至DT50Gy,多发转移灶者给予全颅放疗DT45Gy。结果:治疗后89%患者神经系统症状改善,对脑转移灶的客观有效率为68.3%(28/41),对肺原发灶的有效率为39.0%(16/41),主要不良反应为骨髓抑制和脱发,中位生存期9.8个月,1a生存率36.6%(15/41)。结论:同步放化疗治疗肺癌脑转移患者有效率和生存率均较高,且患者耐受性好。
OBJECTIVE: To observe the efficacy, adverse reactions and survival rate of teniposide and cisplatin combined with brain radiation in patients with brain metastases of lung cancer. Methods: Teniposide 100mg, the first day to the third day; cisplatin 40mg, the first day to the third day, 21d for a cycle. Cerebral radiotherapy was started on the fifth day after the start of the first cycle of chemotherapy. DT (1.8-2.0) Gy / time, once / d, 5 times / week and DT30Gy systole was added to DT50Gy in a single lesion. Multiple metastases were given whole-cell radiotherapy DT45Gy. Results: After treatment, 89% of patients had improvement of neurological symptoms, objective response rate of brain metastases was 68.3% (28/41), effective rate of primary lung tumors was 39.0% (16/41), the main adverse reactions were Myelosuppression and hair loss, the median survival of 9.8 months, 1a survival rate of 36.6% (15/41). Conclusions: The efficiency and survival rate of concurrent chemoradiotherapy in the treatment of patients with brain cancer with lung cancer are high and the patients are well tolerated.